Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Fiber Before Meals Is the Natural GLP-1 Hack

by Team Lumida
March 11, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
Fiber Before Meals Is the Natural GLP-1 Hack
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key takeaways

Powered by lumidawealth.com

  • Fiber stimulates GLP-1, the same hormone targeted by popular weight-loss drugs.
  • Eating fiber before meals reduces appetite and slows glucose spikes.
  • It improves gut health, which plays a central role in metabolism and inflammation.
  • Consistent fiber intake is linked to lower obesity, diabetes, and cardiovascular risk.

What Happened?

GLP-1 drugs like Ozempic and Wegovy work by increasing a hormone that slows digestion and signals fullness to the brain. But the body already produces GLP-1 naturally. One of the strongest natural triggers is dietary fiber. When fiber reaches the gut, gut bacteria ferment it into short-chain fatty acids that stimulate GLP-1 release, helping regulate appetite and blood sugar.

Why It Matters?

Most people consume far less fiber than recommended. Low fiber intake contributes to unstable blood sugar, overeating, and metabolic dysfunction. Increasing fiber intake can naturally activate the same hormonal pathways targeted by weight-loss medications, supporting better appetite control and metabolic health without drugs.

Fiber also feeds beneficial gut bacteria, which influences inflammation, insulin sensitivity, and long-term disease risk.

What to Do

A simple habit can amplify this effect:

  • Eat vegetables or fiber-rich foods before your main meal
  • Aim for 25–35 grams of fiber per day
  • Prioritize beans, lentils, oats, vegetables, berries, and seeds

This approach slows digestion, improves satiety, and stabilizes blood sugar — one of the simplest daily habits for metabolic health and longevity.

Previous Post

Stocks Rebound as Oil Drops Below $90, but Markets Are Still Trading on Fragile Relief

Next Post

Amazon’s Court Win Against Perplexity Escalates the Fight Over Who Owns the AI Shopping Customer

Recommended For You

US Alcohol Consumption Holds at Historic Low as Majority of Americans Now Say Drinking Is Bad for Health

by Team Lumida
6 days ago
clear drinking glass with ice cubes

A Gallup poll of 1,200 adults finds 54% of Americans consume alcohol — matching last year's historic low and halting three consecutive annual declines — while 51% now...

Read more

Big Food’s GLP-1 Reckoning: Conagra, Kraft, and Packaged-Food Giants Reformulate for the Not-So-Hungry

by Team Lumida
7 days ago
pasta with red sauce on white ceramic round plate

As GLP-1 weight-loss drugs suppress appetite across millions of households, packaged-food companies are retooling recipes, portion sizes, and sensory profiles to win over consumers who eat less but...

Read more

Novo Nordisk Tests Low-Dose Wegovy Pills as Most Patients Already Stick to Smallest Doses

by Team Lumida
7 days ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has launched a 450-person trial to determine the minimum effective dose of its oral Wegovy pill — a clinically significant shift given that more than two-thirds...

Read more

4 in 5 Americans Say Healthcare Costs Are the Nation’s Top Health Problem — and Nobody Agrees on Who Should Fix It

by Team Lumida
1 week ago
doctor holding red stethoscope

A Commonwealth Fund survey of 25,873 adults finds near-universal alarm over health insurance premiums and out-of-pocket costs, even as ACA marketplace premiums surge 58% in 2026 and nearly...

Read more

Wealthy, Healthy, and Ready to Spend: Baby Boomers Are Driving a Global Travel Boom the Industry Is Racing to Serve

by Team Lumida
1 week ago
couple kissing on the road during daytime

Baby boomers — flush with retirement savings and in better health than previous generations — are fueling a high-end travel surge, with the industry responding with private-plane tours,...

Read more

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
2 weeks ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
2 weeks ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more

Patients Are Using AI to Interpret Their Medical Test Results Before Seeing Doctors — And Doctors Are Struggling to Untangle the Errors

by Team Lumida
3 weeks ago
doctor holding red stethoscope

Roughly a third of American adults now consult AI for health advice, and the majority view test results online before speaking with a doctor — a trend accelerated...

Read more

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
4 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
4 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more
Next Post
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon’s Court Win Against Perplexity Escalates the Fight Over Who Owns the AI Shopping Customer

a building that has a sign on the side of it

Costco Faces Lawsuit Over Potential Tariff Refunds

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Home Sellers Who Overprice Are Taking Big Hits as High Rates Drag Out Sales

Home Sellers Who Overprice Are Taking Big Hits as High Rates Drag Out Sales

December 3, 2025
Retailers Rush Back Into Brick-and-Mortar as Vacancies Tighten and Consumer Spending Holds Up

Retailers Rush Back Into Brick-and-Mortar as Vacancies Tighten and Consumer Spending Holds Up

December 3, 2025
Deutsche Bank: U.S. Consumers Embrace Crypto, Question Stablecoins’ Future

Deutsche Bank: U.S. Consumers Embrace Crypto, Question Stablecoins’ Future

September 12, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018